Zhejiang Orient Gene Biotech Co.,Ltd

Equities

688298

CNE100003RM8

Medical Equipment, Supplies & Distribution

End-of-day quote Shanghai S.E. Other stock markets 03:30:00 01/07/2024 am IST			5-day change	1st Jan Change
26.25 ^CNY	-3.31%		-7.37%	-26.59%

12/06	US FDA Grants Emergency Use Authorization to Orient Gene Biotech's COVID-19 Test Kit	MT
16/05	Orient Gene Biotech's US Unit Gets FDA Clearance for Fentanyl Detectors	MT

An unknown buyer acquired 6.14% stake in Zhejiang Orient Gene Biotech Co., Ltd. from a Shareholder.

July 20, 2021

An unknown buyer acquired 6.14% stake in Zhejiang Orient Gene Biotech Co., Ltd. (SHSE:688298) from a Shareholder on July 20, 2021. Shareholder And Parties Acting In Concert reduced its stake in Orient Gene Biotech to 8.40% from 14.54%. An unknown buyer completed the acquisition of 6.14% stake in Zhejiang Orient Gene Biotech Co., Ltd. (SHSE:688298) from a Shareholder on July 20, 2021.

Latest news about Zhejiang Orient Gene Biotech Co.,Ltd

US FDA Grants Emergency Use Authorization to Orient Gene Biotech's COVID-19 Test Kit	12/06	MT
Orient Gene Biotech's US Unit Gets FDA Clearance for Fentanyl Detectors	16/05	MT
Zhejiang Orient Gene Biotech Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	29/04	CI
Zhejiang Orient Gene Biotech's Unit Gets US FDA's Nod to Register Two Products	23/04	MT
Zhejiang Orient Gene Biotech Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	28/02	CI
Zhejiang Orient Gene Biotech Co.,Ltd announces an Equity Buyback for CNY 100 million worth of its shares.	08/02	CI
Zhejiang Orient Gene Biotech Co.,Ltd authorizes a Buyback Plan.	07/02	CI
Zhejiang Orient Gene Obtains Veterinary GMP Certificate, Production License	08/01	MT
Zhejiang Orient Gene Biotech Co.,Ltd(SHSE:688298) dropped from Shanghai Stock Exchange Health Care Sector Index	08/12	CI
Zhejiang Orient Gene Biotech Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	30/23/30	CI
Zhejiang Orient Gene Biotech Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	29/23/29	CI
Orient Gene Biotech Registers New In Vitro Diagnostic Reagents	13/23/13	MT
Zhejiang Orient Gene Biotech Elects Chairman, Vice Chairman	01/23/01	MT
Zhejiang Orient Gene Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	27/23/27	CI
Zhejiang Orient Gene Registers Two Medical Devices in EU, US	24/23/24	MT
Zhejiang Orient Gene Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	27/23/27	CI
IN BRIEF: Omega Diagnostics receives CD4 deferred consideration	25/22/25	AN
Zhejiang Orient Gene Biotech Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	30/22/30	CI
Zhejiang Orient Gene Biotech Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	29/22/29	CI
Omega Diagnostics Up 16% With Sale Of Loss-Making CD4 Business	03/22/03	MT
ZXBio, Inc. announced that it has received $3.1 million in funding from Zhejiang Orient Gene Biotech Co., Ltd.	08/22/08	CI
Zhejiang Orient Gene Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	27/22/27	CI
Zhejiang Orient Gene Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	25/22/25	CI
Omega Diagnostics Shares Plunge on $1.4 Million Sale of Loss-making Business to Chinese Biotech	11/22/11	MT
MSCI to Add Gree, Three Gorges Renewables, Others to China Indices	11/22/11	MT

Chart Zhejiang Orient Gene Biotech Co.,Ltd

Duration

Period

Chart Zhejiang Orient Gene Biotech Co.,Ltd

More charts

Company Profile

Zhejiang Orient Gene Biotech Co., Ltd. is a China-based company principally involved in the research, development, manufacture and sales of in-vitro diagnostic products. The Company's main products are Point of Care Testing (POCT) instant diagnostic reagents, which are mainly used in drug testing, infectious disease testing, eugenic testing, tumor marker testing and cardiac marker testing. The Company also engages in the manufacture and sales of biochemical diagnostic reagents used for dry biochemical diagnostics and biochemical fluid diagnostics. The Company operates its businesses in Mainland China, America, Europe, Asia, Africa and Oceania.

Sector

Medical Equipment, Supplies & Distribution

Calendar

27/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
ZHEJIANG ORIENT GENE BIOTECH CO.,LTD	-26.59%	753M
BIOMÉRIEUX	-10.83%	11.24B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-15.14%	7.29B
LANTHEUS HOLDINGS, INC.	+28.50%	5.57B
DIASORIN S.P.A.	+0.04%	5.31B
AUTOBIO DIAGNOSTICS CO., LTD.	-19.93%	3.68B
ANDON HEALTH CO., LTD.	+7.75%	2.58B
10X GENOMICS, INC.	-66.03%	2.33B
VITROLIFE AB	-11.20%	2.23B
MYRIAD GENETICS, INC.	+25.55%	2.21B

Diagnostic & Testing Substances